Sipavibart

BIOLOGICAL2 trials

Sponsors

AstraZeneca AB, Nancy Klimas

Conditions

COVID-19Post-COVID / Long-COVID

Phase 2

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

RecruitingNCT07021794

Nancy KlimasPost-COVID / Long-COVID

Start: 2025-06-16End: 2026-12-31Target: 100Updated: 2025-08-05

Phase 3

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment

CompletedCTIS2024-512554-15-00

AstraZeneca ABCOVID-19

Start: 2023-06-21End: 2025-02-07Target: 533Updated: 2025-02-28